Highlights from EAU 2017 - Results from #20

Viewing 21-40 of 138 articles

EAU 2017: Discussant: Is PIRADS 2.0 standardized enough?

EAU 2017: Reading and interpreting mpMRI: PIRADS 2.0

EAU 2017: European Society of Urogenital Radiology (ESUR) lecture PI-RADS in clinical practice including differential diagnoses in prostate imaging

EAU 2017: Metastases and death after 15 year of follow-up in men with screen-detected low-risk prostate cancer treated with protocol based active surveillance, radical prostatectomy or radiotherapy (804)

EAU 2017: MRI as a follow up tool in active surveillance: results from an MRI-defined active surveillance cohort

EAU 2017: Multiparametric MRI represents an added value but not a substitute of follow-up biopsies in patients on active surveillance for low-risk prostate cancer

EAU 2017: Pathological findings at radical prostatectomy after initial active surveillance in low-risk prostate cancer patients. Did we miss the chance to cure?

EAU 2017: PTEN status in diagnostic biopsies predicts active surveillance rebiopsy Gleason upgrade, treatment change and adverse surgical histopathological findings

EAU 2017: Variation in the use of active surveillance for low-risk prostate cancer

EAU 2017: Metastases and death after 15 year of follow-up in men with screen-detected low-risk prostate cancer treated with protocol based active surveillance, radical prostatectomy or radiotherapy

EAU 2017: MRI as a follow up tool in active surveillance – results from an MRI-defined active surveillance cohort (387 men, median 5 year follow up)

EAU 2017: Risk-based selection for active surveillance: Results of the Movember Foundation’s Global Action Plan prostate cancer active surveillance (GAP3) initiative

EAU 2017: Variation in the use of active surveillance for low-risk prostate cancer

EAU 2017: State-of-the-art Lecture: EAU Guidelines on mCRPC – An Update

EAU 2017: Is There a Role for Local Treatment of Oligometastatic Disease? No

EAU 2017: Is There a Role for Local Treatment of Oligometastatic Disease? Yes

EAU 2017: State-of-the-art lecture Hereditary Prostate Cancer

EAU 2017: Active Surveillance for 3+4=7 Prostate Cancer - Pro

EAU 2017: Lessons from the ProtecT trial

EAU 2017: Con – mpMRI targeted biopsies are sufficient

1
2
3
4
5
6
7